Mark Brosius Sells 492 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 492 shares of Intuitive Surgical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $573.78, for a total transaction of $282,299.76. Following the completion of the sale, the senior vice president now owns 4,056 shares of the company’s stock, valued at $2,327,251.68. This represents a 10.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Intuitive Surgical Price Performance

ISRG opened at $557.96 on Wednesday. The firm has a market cap of $198.73 billion, a P/E ratio of 87.05, a PEG ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The company has a 50 day simple moving average of $571.08 and a two-hundred day simple moving average of $530.63.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds have recently modified their holdings of the company. M.E. Allison & CO. Inc. bought a new position in shares of Intuitive Surgical during the fourth quarter worth $449,000. Seilern Investment Management Ltd bought a new position in shares of Intuitive Surgical during the fourth quarter worth $82,517,000. Sycomore Asset Management boosted its position in shares of Intuitive Surgical by 27.4% during the fourth quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider’s stock worth $9,214,000 after acquiring an additional 4,079 shares during the last quarter. Exome Asset Management LLC boosted its position in shares of Intuitive Surgical by 16.8% during the third quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider’s stock worth $3,649,000 after acquiring an additional 1,069 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Intuitive Surgical by 5.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,843 shares of the medical equipment provider’s stock worth $5,138,000 after acquiring an additional 525 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ISRG has been the subject of a number of research analyst reports. Raymond James lifted their price target on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. UBS Group boosted their target price on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, BTIG Research boosted their target price on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.